SFA Therapeutics Announces FDA Approval To Begin IND Trial
Astro Bug/10083363
Trending...
- Financial Solutions Inc. Receives the 2020 Best of Sheridan Wyoming Award
- Former CEO & Founder of Five Star Custom Foods, Acquired by Cargill, Joins CEO Coaching International
- West Coast Recording Artist, Composer and Actor, Blue Ragg$ Releases New Music & Theatrical Video
Clinical Trial Examines Human Micro-biome-based Drug SFA002 In Mild to Moderate Plaque Psoriasis
PHILADELPHIA - AstroBug -- SFA Therapeutics, Inc. is pleased to announce that the US FDA has provided approval to conduct a clinical trial (officially referred to as an IND) for the treatment of "the appearance of the structure of skin with plaques due to psoriasis." SFA plans to expand the evaluation of one of its five microbiome-derived drugs, SFA002, in this new trial.
This 30-subject open-label clinical trial in patients with mild-to-moderate psoriasis will enroll 15 patients into treatment with an initial formulation of SFA002 and an additional 15 subjects into treatment with a second formulation. Treatment duration will be three months, after which patients will be observed for an additional three months.
The Need for an Oral Treatment of Mild to Moderate Psoriasis Remains Acute
More on Astro Bug
"Significant clearing of psoriatic plaques has already been demonstrated with SFA002 in a small study," commented SFA CEO Dr. Ira Spector, "and, because we know that this patient group has lacked an effective and safe oral treatment option, we are going into this larger IND trial with considerable optimism."
Study recruitment is planned to begin in the Fall of 2020. Following the trial's completion, SFA expects to finalize the SFA002 formulation and proceed into a randomized controlled clinical trial.
Please contact SFA Therapeutics COO, James Kirwin, at jameskirwin@sfatherapeutics.com for additional information.
About SFA Therapeutics
SFA Therapeutics, Inc. is a bio-pharmaceutical company focused on new human-microbiome-based advancements in the treatment of inflammatory diseases, targeting NF-kB and RAS. Chronic inflammation has been implicated in a wide range of diseases, including HCC, Psoriatic Arthritis, Rheumatoid Arthritis, Lupus (SLE), Inflammatory Bowel Disease (IBD), Crohn's Disease, Liver Disease and relapse/recurrence in AML and CML. SFA currently has five drugs under development, and is targeting Psoriasis, Hepatitis B and Hepatocellular Carcinoma (liver cancer) with their lead assets.
More on Astro Bug
SFA's small-molecule drugs are derived from natural substances produced in the human microbiome and enable a new platform for developing safer treatments for inflammatory diseases. SFA's drug development platform has been exclusively licensed from Temple University to SFA Therapeutics in Jenkintown, PA. Please visit sfatherapeutics.com to learn more.
This 30-subject open-label clinical trial in patients with mild-to-moderate psoriasis will enroll 15 patients into treatment with an initial formulation of SFA002 and an additional 15 subjects into treatment with a second formulation. Treatment duration will be three months, after which patients will be observed for an additional three months.
The Need for an Oral Treatment of Mild to Moderate Psoriasis Remains Acute
More on Astro Bug
- The Atlas Group adds Corbin Raines to their list of professional property managers
- Latino Leaders Network to Honor Tucson Mayor Regina Romero with the Antonio Villaraigosa Leadership Award at the 34th Tribute to Mayors
- The UK's Leading Digital Marketing Agency, Finsbury Media Announces Employees Will Be Allowed To Work From Home:
- NMEA 2000 Development and Prototyping Boards for Marine Applications
- ICTBroadast Version 4.1, Advance call center software for your needs
"Significant clearing of psoriatic plaques has already been demonstrated with SFA002 in a small study," commented SFA CEO Dr. Ira Spector, "and, because we know that this patient group has lacked an effective and safe oral treatment option, we are going into this larger IND trial with considerable optimism."
Study recruitment is planned to begin in the Fall of 2020. Following the trial's completion, SFA expects to finalize the SFA002 formulation and proceed into a randomized controlled clinical trial.
Please contact SFA Therapeutics COO, James Kirwin, at jameskirwin@sfatherapeutics.com for additional information.
About SFA Therapeutics
SFA Therapeutics, Inc. is a bio-pharmaceutical company focused on new human-microbiome-based advancements in the treatment of inflammatory diseases, targeting NF-kB and RAS. Chronic inflammation has been implicated in a wide range of diseases, including HCC, Psoriatic Arthritis, Rheumatoid Arthritis, Lupus (SLE), Inflammatory Bowel Disease (IBD), Crohn's Disease, Liver Disease and relapse/recurrence in AML and CML. SFA currently has five drugs under development, and is targeting Psoriasis, Hepatitis B and Hepatocellular Carcinoma (liver cancer) with their lead assets.
More on Astro Bug
- CEO of Industrial Giant ABB in Brazil Joins CEO Coaching International
- Fighting Pest Problems with The Safest Pest Control Dubai Residents Can Get
- Best Advertising Methods To Attract People To Your Events Post COVID-19 by Duluth Businessman Ismail Sirdah
- Thirteen MBK Senior Living Communities Receive "2021 Best of Senior Living" Distinction
- Grassroots Advocacy Group Urges Biden Administration to Appoint a Doctoral Level Mental Health Professional to Lead SAMHSA
SFA's small-molecule drugs are derived from natural substances produced in the human microbiome and enable a new platform for developing safer treatments for inflammatory diseases. SFA's drug development platform has been exclusively licensed from Temple University to SFA Therapeutics in Jenkintown, PA. Please visit sfatherapeutics.com to learn more.
Source: SFA Therapeutics, Inc.
0 Comments
Latest on Astro Bug
- Fifth Gen Media announces Darlene Pope as Chairman of the Advisory Council
- Phinge To Launch Netverse, a Rewards-Based Alternative to Apple and Google Using Innovative Proprietary Technology and Patented Mobile Devices
- Spivey Hall Children's Choir Looks To 2021 Through The Lens of Langston Hughes Poetry
- Dancin' Delivery Adds Pets To Its List Of Delivery Services
- Wohler releases AoIP & Analog options for their iVAM1-1
- While Supplies Last: Thermal Transfer Label Sale
- The Business Consultant behind The First Black-owned BP
- Overstock Promo: Thermal Transfer Labels On Sale Now
- Weddings Beautiful Worldwide announces Jacqueline Vazquez as new CEO
- Dr. Linda Howe releases new book, Inspired Manifesting
- Official CMT Artist Ashley Wineland to Release Title Track from Upcoming Album 'I'm Gonna Ride'
- Why Medical Massage Means More Guarantees of Pain Relief for Massage Patients in Los Angeles
- Low-Cost Colour Printing with the Epson WorkForce WF-C879R High Speed Office Inkjet Printer
- BitRouter Announces 3pi ATSC 3.0 Receiver for Automotive and Distance Learning Applications
- Love vs. Design Launches With Instantly Customizable Peel And Stick Wallpapers For Your Home
- Latin Pop/Rock group Al Cielo - First Time Meeting In Person
- Play FLIP FORWARD by Autonomous & You Might Find Yourself $2000 Richer!
- Spice Resto-Lounge Welcomes Actor & Entertainer Alex Castro As New Entertainment Director
- An Irish-US Partnership of Note
- NEAT Elite Glass Now Available Worldwide